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ABSTRACT
Invasive mycoses have assumed great importance in recent years. Most infections are caused by Candida
spp. but the emergence of fungal infections caused by Aspergillus spp. and other ﬁlamentous fungi is
changing the spectrum of these diseases. Immunosuppression and the breakdown of anatomical barriers
are the major risk-factors for fungal infections. Patients more prone to suffer invasive mycoses are found
in various clinical settings, including haematology services, transplantation, oncology and intensive care
units. The most serious infections afﬂict patients with haematological malignancy and prolonged and
profound neutropenia. These patients have non-speciﬁc symptoms that make diagnosis very difﬁcult.
The recovery of fungi from blood, as well as other deep clinical specimens, remains an insensitive
marker for the diagnosis of invasive mycoses. Antigen assays, e.g., (1 ﬁ 3)-b-D-glucan (BG) and
galactomannan (GM) detection, are undergoing clinical validation. BG may be present in the blood of
patients with infections caused by a wide variety of fungi, including Candida, Aspergillus and Fusarium.
GM may be detected in blood very early in the course of invasive aspergillosis and be positive prior to
the clinical suspicion of infection. However, the aetiology of GM false-positives has still to be completely
elucidated. DNA detection by PCR is under investigation, and tests will require adaptation and
validation before clinical use.
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Mycoses have recently assumed great importance,
and their incidence has increased in persons with
haematological malignancies and in many other
immunocompromised patients. Most infections
are caused by Candida spp. but the emergence of
Aspergillus spp. and other fungi as aetiological
agents is continuously changing the spectrum of
disease. Immunosuppression and the breakdown
of anatomical barriers are major risk-factors.
At-risk patients can be found in various clinical
settings, including AIDS clinics as well as inten-
sive care, transplantation and oncology units.
Moreover, most fungal infections have non-spe-
ciﬁc symptoms, making diagnosis difﬁcult, and
prompt initiation of antifungal therapy is critical
in improving the outcome of disease [1,2]. Thus,
antifungal agents are administered empirically to
those patients with a high suspicion of invasive
mycoses, even when the presence of infection
cannot be documented [3,4]. Aspergillosis and,
perhaps, mucormycosis (zygomycosis) are the
most frequent mycoses caused by ﬁlamentous
fungi. Although many publications highlight
clinical problems with invasive mycoses caused
by unusual mould species, e.g., Scedosporium
proliﬁcans, Pseudallescheria boydii (Scedosporium
apiospermum) and Fusarium spp., the incidence of
such mycoses is extremely low [5–7].
Mucormycosis is a rare life-threatening
fungal opportunistic infection, occurring
mostly in predisposed diabetic patients and
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immunocompromised persons, being most com-
monly caused by Rhizopus spp. [8]. Rhizopus and
other mucorales, e.g., Mucor, Rhizomucor and
Absidia, cause a severe angioinvasive infection
with very high mortality rates. Iron metabolism
plays a central role in the pathogenesis of these
infections, and deferoxamine predisposes patients
by supplying the fungus with iron. A diagnosis of
mucormycosis is rarely suspected among haema-
tology patients, and most clinicians presume a
diagnosis of invasive aspergillosis. In this group of
patients, an ante-mortem diagnosis of mucormy-
cosis is made in only 20–50% of cases [9]. The
evolution of this fungal infection is frequently fatal
unless aggressive treatment is started early and
predisposing factors are handled effectively [10].
Invasive aspergillosis is relatively frequent in
neutropenic patients, being a major cause of
morbidity and mortality, in part due to the
difﬁculty in making a clear diagnosis at an early
stage of the disease [11,12]. Such mycosis occurs
in 0.5–15% of patients who undergo allogeneic
haematopoietic stem-cell transplants [13,14], in a
smaller proportion of patients who undergo
solid-organ transplant (0.1–3%), especially of
the lung, kidney and heart [14,15], and among
patients treated for haematological malignancy
[16,17]. The high mortality rate (50–90%) is due
in part to the difﬁculties in achieving a timely
diagnosis because symptomatology and radiolo-
gical signs are often non-speciﬁc or have been
attenuated by some treatments, e.g., corticoster-
oid therapy [4,14,18,19]. In many cases, the
diagnosis begins after patients present with
persistent fever despite antibacterial therapy or
develop pulmonary inﬁltrates during the treat-
ment. Fever is a sign with very low speciﬁcity,
and thoracic radiology also has a poor sensitivity,
due to neutropenia. Although radiographs or
high-resolution computed tomography (CT)
scans may suggest the diagnosis of invasive
aspergillosis, their ﬁndings are neither speciﬁc
nor sensitive [20]. The diagnosis is frequently
established post-mortem, as two studies by
Young et al. [21] and Groll et al. [22] make clear.
In the former study [21], clinical diagnosis of
invasive aspergillosis had not been made in 68%
of patients who had evidence of disease at
autopsy. The latter autopsy study showed that,
over the period 1988–1992, 68% of patients with
invasive aspergillosis were not treated with
antifungal drugs [22].
Traditional microbiological methods, e.g.,
direct microscopy and culture of respiratory
specimens or blood, have low sensitivity and give
positive results only at late stages of invasion [23].
In many cases, the increase in the number of
neutropenic patients and the risk of invasive
mycoses are leading to overestimation of the
potential clinical signiﬁcance of many fungal
isolates [24]. Among Aspergillus species, Aspergil-
lus fumigatus represents c. 70% of clinical isolates
of medical importance [25]. Other species, such as
Aspergillus ﬂavus (c. 15%), Aspergillus niger
(c. 7%), and Aspergillus terreus (c. 5%), are isola-
ted at lower frequencies. Proof of invasive asper-
gillosis can be obtained only by observing
Aspergillus growth in deep tissues and culturing
the microorganism from the same specimen.
Ante-mortem invasive procedures, e.g., histolog-
ical examination and culture of biopsy specimens,
require an aggressive approach that often pre-
cludes their use in many of these patients because
of profound thrombocytopenia, hypoxaemia, or
their generally critical condition [26]. Moreover,
the infection is usually advanced and the fungal
burden is high. However, a recent study [27]
showed that radiologically guided, ﬁne needle
biopsies provided a high diagnostic yield and
could be performed without complications.
Unfortunately, in several cases, a false-negative
result was obtained, and therapeutic decisions
could not be made solely on the basis of the
biopsy result [27]. Bronchoalveolar lavage (BAL)
ﬂuid appears to be an optimal specimen, and
culture of BAL ﬂuid contributes to the diagnosis
in 30–50% of patients suffering from pulmonary
aspergillosis. However, the decision to perform
bronchoscopy is made after pulmonary inﬁltrates
are detected by radio-diagnostic techniques in
patients with persistent fever, which may delay
the diagnosis [28,29]. These common problems in
the management of invasive mycoses have
induced the European Organisation for Research
and Treatment of Cancer ⁄ Invasive Fungal Infec-
tions Cooperative Group (EORTC-IFICG) and the
National Institute of Allergy and Infectious Dis-
eases Mycoses Study Group (NIAID-MSG) [26] to
classify invasive aspergillosis episodes into three
different categories—proven, probable and poss-
ible—to facilitate the comparison of research trials
of new diagnostic tests and antifungal treatment.
Under this classiﬁcation, an episode is considered
to be proven invasive aspergillosis if positive
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cultures are obtained from sterile sites or invasive
growth of the microorganism is demonstrated in
tissue specimens from the infected site. The
presence of positive cultures and abnormal radi-
ographic ﬁndings are categorised as probable
fungal disease, and persistent fever or clinical
failure of treatment with antibacterial agents as
possible fungal disease.
This article reviews the main new data on rapid
diagnosis of invasive mycoses, with an emphasis
on the diagnosis of invasive aspergillosis.
ALTERNATIVE METHODS FOR THE
DIAGNOSIS OF INVASIVE MYCOSES
An ideal test for diagnosing an invasive mycosis
should have good performance characteristics,
ensure a high level of certainty with respect to the
presence or absence of disease, and become
positive at an early stage of infection [30]. No
single test with all these features is available, and
thus a combination of information from different
laboratory tests and clinical procedures is
required. In recent years, a number of rapid
diagnostic techniques have become available for
the diagnosis of invasive mycoses caused by
ﬁlamentous fungi and can be very useful for the
speciﬁc diagnosis of invasive aspergillosis:
CT-scan and non-culture-based methods such as
detection of circulating fungal markers: (1 ﬁ 3)-b-
D-glucan (BG) [12,23,31,32], galactomannan (GM)
[11,12,23,32–37] or fungal DNA [35,37–40]. BG
and common sequences of fungal DNA can be
considered pan-fungal markers. Detection of GM
and Aspergillus-speciﬁc DNA by means of PCR
could allow a more accurate diagnosis of an
invasive aspergillosis. These techniques, when
combined with risk stratiﬁcation as described by
Prentice et al. [41] or Gavalda et al. [42], may
permit early diagnosis of invasive mycoses and
the implementation of pre-emptive therapeutic
strategies that are especially useful in patients
with neutropenia [11].
Neutropenic patients are prone to a variety of
pulmonary complications, and CT-scan is an
excellent way to detect pulmonary abnormalities
[43]. However, the ﬁndings are generally non-
speciﬁc and their usefulness depends on the
pathogen causing the pulmonary infection, the
level of immunosuppression and the underlying
disease of the patient. Several characteristic
lesions that are highly suggestive of fungal
infection have been described. In neutropenic
patients, pulmonary mycosis often manifests in
early stages as a nodule surrounded by a halo of
ground-glass attenuation (‘halo sign’). Typical
cavities may occur in later stages of infection,
often after recovery of the aplasia [44]. CT-scan
has proved to be a very useful tool when used
very early and systematically in cases of febrile
neutropenia, and the survival rate of patients
improved when systematic CT-scan was com-
bined with prompt antifungal treatment and
surgery [45]. The availability of CT-scan may be
limited in many centres, and patients must leave
their protected environment to undergo imaging
[30]. Circulating fungal markers are used as an
early indicator of opportunistic mycoses and as a
tool to evaluate response to treatment. Further-
more, fungal markers can be used to classify the
groups of patients with a higher degree of
certainty of infection in clinical trials for evalua-
tion of new antifungal drug efﬁcacy. Some of
these assays, e.g., GM and BG, are being used in
many hospitals and form part of the diagnostic
strategy in combination with other procedures
such as CT-scan [20]. PCR detection of fungal
DNA in blood or BAL specimens is a promising
tool, but a standardised, commercialised format is
not available at present [39,40].
GALACTOMANNAN DETECTION
The early reports of antigen detection for diagno-
sis of invasive aspergillosis were encouraging
[46]. The Pastorex Aspergillus GM latex agglutin-
ation kit was introduced in the 1990s, but since
1995 it has been largely replaced by the Platelia
Aspergillus kit (Bio-Rad, Marnes-La-Coquette,
France) [47–49]. Platelia Aspergillus is a commer-
cial sandwich ELISA that uses the EB-A2 rat
monoclonal antibody, which recognises b-1–5-
linked galactofuranose [50] of GM released by
different species of Aspergillus and several other
fungi (Table 1). GM can be detected in the
infected tissues and also in body ﬂuids, including
serum (detection limit: 0.5–1 ng ⁄mL), urine, BAL
ﬂuid, pericardial ﬂuid and cerebrospinal ﬂuid
(CSF) [48]. Furthermore, the assay has been
reported to give a high number of positive results
in neonates and other paediatric patients without
invasive aspergillosis (Table 2). Absorption of
GM through altered mucosa from the gastroin-
testinal tract of patients receiving cytotoxic
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chemotherapy is a potential source of false-pos-
itive reactivity [30,51]. Another possible aetiology
for false-positive reactions is bacterial lipoteichoic
acid, which has been suggested to cross-react with
the EB-A2 monoclonal antibody because of a
molecular structure similar to GM side chain
residues [52]. The lipoteichoic acid antigen is
found in the cell wall of biﬁdobacteria, a group of
bacteria present in high concentrations in the
gastrointestinal microbiota of neonates [20]. False-
negative reactivity has been reported in 8–10% of
patients with documented invasive aspergillosis
[53]. The cause of false-negative results is
unknown, but the variability in GM production
and its release by different species and strains of
Aspergillus or anti-GM antibody production by
patients might interfere with this test [34]. The
level of angioinvasion by Aspergillus could also
affect the release of GM from a localised infection
[30].
The prospective detection of GM in patients at
high risk for invasive aspergillosis has shown that
the Platelia Aspergillus test is highly speciﬁc (81–
93%). However, the reported sensitivity varies
widely, between 30% and 100%, because of
several factors [3,4,11,31,33,34,37,53–63]. One of
these factors is the cut-off value of a positive GM
result. In Europe, the manufacturer initially
recommended an index of 1.5, while in the USA
0.5 is the currently recommended cut-off value.
Many authors have used other cut-off values in
their evaluation of the diagnostic potential of this
kit [48]. Studies evaluating the inﬂuence of the
different cut-off values on the sensitivity and
speciﬁcity values of Platelia Aspergillus have
been recently reviewed by Wheat [48,49], and
some of the most recent are shown in Table 3.
Detection of GM appears to be a useful tool for the
early diagnosis of invasive aspergillosis in
patients with haematological malignancy
[3,4,31,33,37,53,57,62,64]. A positive result may
help in choosing the most effective antifungal
treatment. Negative results might provide a basis
for further diagnostic tests or for selecting the
appropriate empirical therapy against moulds
potentially resistant to antifungal drugs active
against Aspergillus spp.
For maximum sensitivity, the test should be
performed at least twice-weekly during hospital-
isation [32]. In a prospective, pathology-controlled
Table 1. Fungal galactomannan detected by EB-A2 mono-
clonal antibody (Pastorex Aspergillus and Platelia Asperg-
illus kits)
Genus Detection Reference
Aspergillus Yes [48]
Acremonium Yes [91]
Alternaria Yes [91]
Botrytis Yes [92]
Cladosporium Yes [92]
Fusarium Yes [91]
Mucor No [30]
Paecilomyces Yes [78]
Penicillium Yes [92]
Rhizopus No [30]
Rhodotorula Yes [91]
Trichophyton Yes [92]
Wangiella Yes [91]
Wellemia Yes [92]
Table 2. Causes of false galacto-
mannanaemia (modiﬁed from
Wheat with permission [48])
Condition Mechanism Reference
Chronic graft vs. host disease
Liver transplantation Autoantibodies [93,94]
Allogeneic haematopoietic
stem-cell transplant
Dietary galactomannan
Premature infants, neonates
and children
Intestinal Biﬁdobacterium [34,95–98]
Dialysis Reduced renal clearance [65,93]
Contamination with cotton Antigenic cross-reactivity
Fungal contamination
(see Table 1)
Fungaemia
Bacteraemia [78,91,92,99]
Cyclophosphamide [100]
Piperacillin–tazobactam
treatment
Amoxicillin–clavulanic acid
treatment
Contamination
with galactomannan
(produced by Penicillium)
[15,55,95,101–106]
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study, a sensitivity and speciﬁcity of 92.6% and
95.4%, respectively, were reported when serial
monitoring was performed [53]. Less frequent
testing following discharge from the hospital may
be appropriate if immunosuppression persists.
The exact frequency of testing in non-hospitalised
patients with chronic graft vs. host disease
depends upon the severity of immunosuppres-
sion. Monitoring following solid-organ transplan-
tation is not recommended for patients with
non-haematological malignancies or disorders
treated with less intense immunosuppression [48].
Furthermore, GM can be detected in the serum
at an early stage of infection, often before symp-
tomatology or radiological abnormalities suggest-
ive of invasive aspergillosis become apparent. In
approximately two-thirds of patients, circulating
antigen could be detected at a mean of 8 days
before diagnosis by other means [20,32]. Detection
of circulating fungal markers may be useful, not
only for diagnosing the mycosis, but also for
assessing the effectiveness of therapy. Declining
GM concentrations have been observed in
patients who responded to antifungal therapy,
and rising concentrations in those with fatal
outcomes [20,32]. However, renal failure may
delay antigen clearance, leading to the mistaken
conclusion that therapy is failing [65]. Conversely,
clinical deterioration in the presence of failing GM
antigen levels supports the exclusion of infection
with other microorganisms, including resistant
moulds. Rebound antigenaemia suggests relap-
sing infection and the need for resumption or
modiﬁcation of therapy [48].
Studies evaluating the diagnostic detection of
GM in body ﬂuids other than serum have been
reviewed by Klont et al. [30] and Wheat [48,49].
Detection of antigen in BAL ﬂuid was superior to
detection in serum in a recent study by Becker
et al. [66]. Sanguinetti et al. [67] described detec-
tion of GM in BAL ﬂuid from all patients with
invasive aspergillosis. Musher et al. [68] reported
that the sensitivity in BAL ﬂuid using a 0.5 cut-off
was 76%, with a speciﬁcity of 94%. These authors
concluded that most patients with negative cul-
tures, but positive GM, could have avoided a lung
biopsy or a second bronchoscopy. Airway colo-
nisation may cause false-positive results in BAL
ﬂuid or with other respiratory specimens, which
may reduce the accuracy of the test in certain
patient groups [69]. The central nervous system is
often involved in patients with disseminated
aspergillosis, and antigen may be detected in
CSF [63,70–73]. Antigen was also detected in CSF
from antigenaemic patients without central ner-
vous system involvement, presumably due to
entry of blood into the CSF caused by a traumatic
lumbar puncture [72]. Detection of antigen in the
CSF in the absence of antigenaemia would pro-
vide compelling evidence of central nervous
system aspergillosis in the appropriate clinical
setting. Antigen detection in other tissues and
ﬂuids has been tested, but the accuracy in those
specimens has not been determined [48].
DETECTION OF (1 ﬁ 3 ) -b -D-GLUCAN,
A PAN-FUNGAL MARKER
BG is a cell-wall component of many fungi, except
Zygomycetes and Cryptococcus [74]. Furthermore,
BG is not present in bacteria, viruses and human
cells, and can be considered as a pan-fungal
circulating marker when detected in human ﬂuids
and tissues. BG reacts with factor G of the
horseshoe crab coagulation cascade, activating
this factor G, which reacts with a chromogenic
substrate [75]. This characteristic feature has
allowed the use of BG detection as a tool for
Table 3. Diagnostic performance of
galactomannan detection (Platelia
Aspergillus, Bio-Rad, France)
Cut-off
index Patientsa
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%) Reference
0.6 24 100 93 55 100 [31]
1.5 8 75 100 – – [59]
1.5 12 66.6 96.6 72.7 95.5 [56]
1.5 4 66.7 98 66.7 98 [61]
1 39 90 98 87 98 [3]
1.5 53 91 94 – – [57]
1 33 93 95 93 95 [53]
aPatients suffering from invasive aspergillosis.
PPV, positive predictive value; NPV, negative predictive value.
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diagnosis of invasive mycoses. There are a num-
ber of commercially available methods to detect
BG (FungiTec G, Seikagaku Kogyo Corp., Tokyo,
Japan; b-D-glucan Test Wako, Wako Pure Chem-
ical Industries, Tokyo, Japan; B-G Star, Maruha
Corp., Tokyo, Japan). A new chromogenic test
(Glucatell, Associates of Cape Cod, Falmouth,
MA, USA) has been recently commercialised, and
preliminary studies have documented its poten-
tial for the diagnosis of most invasive fungal
infections, including candidiasis and aspergillosis
[32,49,74,76].
Obayashi et al. [74], using the FungiTec G test,
observed that patients suffering from invasive
mycoses had high concentrations of BG in plasma.
Oral, urinary and bronchial colonisation by fungi
did not raise the concentration of BG above the
expected cut-off (20 pg ⁄mL). These authors report-
ed a sensitivity of 90% and a speciﬁcity of l00% in
over 200 febrile episodes in patients treated for
haematological malignancy. However, several
studies [31,71,77] have reported a low sensitivity
(50–63%) in BG detection. These results are in
contrast to recent data presented by Pazos et al.
[32], which showed that detection of BG by the
Glucatell test is a quite sensitive tool for the
diagnosis of invasive aspergillosis (sensitivity of
87.5%, speciﬁcity of 89.6%, positive predictive
value of 70% and negative predictive value of
96.3%). This high sensitivity found by Pazos et al.
[32] could be inherent to the Glucatell test, since
commercialised tests for BG detection differ
widely in sensitivity [31,49]. The Glucatell test
has shown sensitivities between 60% and 100%
for the diagnosis of invasive mycosis in patients
with acute myeloid leukaemia receiving antifun-
gal prophylaxis [76,78]. In the analysis of the
Fungitell (Glucatell) assay for FDA clearance
[79], the sensitivity for diagnosis of invasive
aspergillosis was 80% and the speciﬁcity was
81%. Although the existence of differences in the
kinetics of BG release during invasive fungal
infection cannot be ruled out at present, it is
possible that the frequency of sampling (twice-
weekly vs. once-weekly or once per episode) may
increase the sensitivity of the test [31]. Odabasi
et al. [76] used a cut-off of 60 pg ⁄mL with the aim
of detecting patients; however, the use of that
cut-off for the patients studied by Pazos et al.
[32] would have decreased the speciﬁcity and
positive predictive value in comparison with
values obtained by these authors when using
120 pg ⁄mL. Differences in the cut-offs estab-
lished in each study could be responsible for
the differences in sensitivity and speciﬁcity in
BG detection, as can be observed in Table 4.
Kawazu et al. [31] compared the BG Wako test
and the Platelia GM assay (cut-off of 0.6) for
weekly screening of patients at risk for invasive
aspergillosis. The GM assay was superior to the
BG assay: sensitivities of 100% and 55%,
respectively. Furthermore, the positive BG
results occurred later in the course of the
infection than did GM antigenaemia.
One of the problems observed in the detection
of BG is the existence of false-positive results that
decrease the speciﬁcity of the test [31]. BG false-
positives have been related to haemodialysis with
cellulose membranes and bacteraemia [11,74].
However, since BG is a pan-fungal marker that
could detect undiagnosed fungal infections, the
possibility of the presence of an infection caused
by unusual fungi, e.g., Trichosporon spp., Saccharo-
myces spp., Acremonium spp. or Pneumocystis
jiroveci, cannot be totally ruled out. An interesting
feature of the kinetics of BG in patients with false-
positive results is the sudden rise and fall in serum
BG concentrations in the absence of antifungal
Table 4. Diagnostic performance of
(1 ﬁ 3)-b-D-glucan detection (Glu-
catell, Associates of Cape Cod, USA)
Cut-off
(pg ⁄mL) Patientsa
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%) Reference
60 163b 69.9 87.1 83.8 75.1 [107]
80 163b 64.4 92.4 89 75.1 [107]
120 8 87.5 89.6 70 96.3 [32]
60 283c 100 90 ⁄ 96 90 ⁄ 96 100 [76]
60 24 55 93 40 96 [31]
aPatients with invasive aspergillosis.
bPatients with invasive mycoses (ten patients with invasive aspergillosis).
cPatients with haematological malignancies receiving antifungal therapy.
PPV, positive predictive value; NPV, negative predictive value.
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treatment. In patients with proven invasive
infection, BG concentrations showed a constant
rise before clinical and microbiological evidence
of invasive aspergillosis and then decreased and
eventually became negative if the patient respond-
ed to antifungal therapy. However, patients not
responding to antifungal treatment did not show
a decrease, and in some cases, showed a continu-
ous rise in serum BG concentrations [32]. This
type of kinetics is similar to false-positive GM
results, while a more protracted rise in BG in
serum suggests the presence of invasive mycoses
[78]. Currently, the kinetics of BG release from the
infected sites, its circulation in blood and its
clearance are poorly understood, but an import-
ant increase in the concentration of BG (from 60–
90 pg ⁄mL to greater than 120–360 pg ⁄mL) can
occur in the course of 5 days. Therefore, twice-
weekly sampling seems to be reasonable for a BG
screening strategy [32]. Kawazu et al. [31] com-
pared the BGWako test and the Platelia GM assay
(cut-off of 0.6) for weekly screening of patients at
risk for invasive aspergillosis. The GM assay was
superior to the BG assay: sensitivities of 100% and
55%, respectively. Furthermore, the positive BG
results occurred later in the course of the infection
than did GM antigenaemia.
A strategy to overcome the deﬁciencies in
testing for the different markers could be to
combine any of the individual tests with another
fungal marker in an attempt to complement its
diagnostic usefulness. For instance, Pazos et al.
[32] observed that the combination of BG and GM
detection was more effective than either test alone
in diagnosing invasive aspergillosis. Interestingly,
both tests were positive in the same patients with
invasive aspergillosis, and the kinetics of both
markers were very similar, but the BG assay
tended to become positive earlier than the GM
assay. Discrepancies were observed with false-
positive results, since patients without invasive
aspergillosis, but positive by BG detection, were
negative by GM detection, and patients with
false-positive results by GM detection were neg-
ative by BG detection. Consideration of the results
obtained for both markers in combination showed
an improvement in the diagnostic efﬁcacy. The
sensitivity, speciﬁcity and positive and negative
predictive values were 87.5%, 100%, 100%, and
96.3%, respectively. Although it did not improve
the sensitivity of each test, the combination of BG
and GM detection was very useful in conﬁrming
the existence of invasive aspergillosis (both mark-
ers were positive in patients with invasive asper-
gillosis). BG tended to become positive earlier
than GM, and this precocity, and the fact that BG
is a pan-fungal marker of invasive mycoses,
should lead to initiation of the diagnostic workup
of invasive fungal infection when a positive result
is detected and should enable prompt antifungal
treatment with a broad-spectrum antifungal drug.
BG positivity should be conﬁrmed by GM detec-
tion in the case of aspergillosis or by detection of
antibodies to Candida albicans germ tube in the
case of candidiasis [80,81] or, when available, by
PCR, to identify the type of invasive fungal
infection and to exclude the possibility of a
false-positive result [11,32].
DNA DETECTION BY PCR
Detection of fungal DNA by means of PCR
methods using blood or BAL specimens also
appears to be a promising tool, but a standard-
ised, commercialised format is not available.
DNA is usually detected in only a minority of
samples from patients with invasive aspergillosis.
Different diagnostic approaches have been used
for DNA detection: detection of DNA as a
pan-fungal marker targeting the small 18S ribo-
somal DNA [82], or ampliﬁcation of species-
speciﬁc DNA sequences. The potential usefulness
of DNA detection is evident, given that many
opportunistic fungal pathogens grow very slowly
or are difﬁcult to isolate in culture media. How-
ever, many false-positives have been reported as
contamination with fungal DNA and, conversely,
DNA is scarcely detected in serum and other
common clinical specimens used for mycological
diagnosis [83–85].
In a recent study that prospectively evaluated
the use of nested Aspergillus species-speciﬁc PCR,
only 11 or 12 of systematically collected blood
samples obtained from 13 patients with proven
and probable invasive aspergillosis were PCR-
positive [38,40]. The release and circulation of
fungal DNA is variable, or the fungal DNA in the
blood is present at a very low concentration, just
within the lower limit of detection of conventional
PCR assays. Thus, intensive sampling is required
for detection of fungal DNA. Moreover, detection
of very small amounts of DNA in blood could be
resolved by analysis of a larger sample volume,
but it is necessary to investigate certain essential
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variables, e.g., the impact of conditions at the site
of infection on the release of markers or the effect
of antifungal treatments [20,86]. Many of these
studies have been reviewed by Buchheidt et al. in
two recent reviews [39,40].
There have been a relatively high number of
false-positive results in many of these studies
(Table 5). In patients classiﬁed as having possible
or non-invasive aspergillosis, fungal DNA was
detected in the blood. Although the high number
of false-positive samples could be due to contam-
ination [84], the likelihood of contamination has
decreased signiﬁcantly due to technical improve-
ments such as the use of automated PCR detection
systems. An alternative explanation is the detec-
tion of the true presence of DNA in the blood
samples from patients with subclinical Aspergillus
infection. Before invasive aspergillosis becomes
clinically or radiologically evident, the infection
develops subclinically and patients could be
classiﬁed in the group of non-invasive or possibly
invasive aspergillosis. PCR is a very sensitive
assay and could detect circulating fungal DNA as
an early indicator of the presence of an infection.
Real-time or quantitative PCR technology (Light-
Cycler technology or TaqMan technology) com-
bine rapid in-vitro ampliﬁcation of DNA with
immediate detection of the amplicon, reducing
the problems associated with excessive manipu-
lation of samples.
As in the case of BG detection, some studies
have compared DNA detection with the meas-
urement of GM, looking for a better diagnostic
performance and for further understanding of the
kinetics of both fungal markers. Kami et al. [73]
reported a sensitivity of 79% by PCR compared to
58% by GM detection (cut-off index of 1.5 and
consecutive positive results for classiﬁcation as
true positive), and speciﬁcities of 92% by PCR
and 97% by Platelia Aspergillus. Buchheidt et al.
[38] compared nested and real-time PCRs using
the LightCycler technology (Roche Diagnostics,
Indianapolis, IN, USA) with GM detection in a
prospective evaluation of neutropenic patients
and solid-organ transplant recipients. Eleven
cases of invasive aspergillosis were studied, and
the GM cut-off index was 1.5. With a requirement
of consecutive positive results for a true-positive
classiﬁcation, four of 11 cases were positive
according to nested PCR. When the PCR data
were analysed on a per-specimen basis rather
than a per-patient basis, only 21.4% of the nested
PCR-positive specimens were positive by real-
time PCR. Three of nine patients tested for GM
antigenaemia exhibited positive results. When the
PCR-positive samples in the study of Buchheidt
et al. [38] were subjected to quantitative PCR
analysis, there was an increase in fungal burden
with increasing certainty of diagnosis. The lowest
burden was found in the samples from patients
classiﬁed as suffering from non-invasive infec-
tion, and the highest in patients with probable
invasive mycoses. This ﬁnding supports the
concept that increasing fungal burden parallels
the progression of infection from subclinical to
clinical. Although the aim is to diagnose invasive
aspergillosis as early as possible, detection of
fungal DNA in patients with subclinical infection
may complicate clinical validation studies [87].
Bretagne et al. [88] compared GM detection
with competitive PCR for monitoring haemato-
logical patients at risk for invasive aspergillosis in
a retrospective evaluation of frozen specimens.
The sensitivity with PCR was 50% vs. 78% for
GM detection, and speciﬁcity was excellent with
both methods, suggesting that the lower rate of
PCR positivity was caused by more rapid clear-
ance of DNA from the blood than with GM
detection. Challier et al. compared real-time PCR
with GM detection in sera from adults and
children with suspected invasive aspergillosis.
At least two specimens were tested for each
subject over a maximum of 2 months before or
after diagnosis of invasive aspergillosis. None of
the controls was falsely positive in either assay,
Table 5. Diagnostic performance of DNA detection in
bronchoalveolar and blood samples (modiﬁed from Buch-
heidt 2005 with permission [40])
Patientsa Sensitivity (%) Speciﬁcity (%) Reference
Detection of DNA in
bronchoalveolar lavage
samples
74 100 96 [108]
249 64–80 93 [109]
141 93.9 94 [38]
66 45–73 93–100 [110]
Detection of DNA in
blood samples
33 79 92 [73]
54 57–100 57 [109]
165 93.9 94 [38]
24 55 93 [31]
aPatients with invasive aspergillosis.
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while all of the cases were positive in one of the
two assays, supporting the recommendation that
a combination of tests would improve sensitivity
[cited by 49]. More recently, Musher et al. [68]
compared the GM assay with PCR in BAL
specimens. With a cut-off of 0.5, the sensitivity
was 76%, compared to 67% with PCR. The
speciﬁcity was 94% with GM detection vs. 100%
with PCR. Combined testing achieved the highest
sensitivity and possibly reduced the need for
invasive procedures. These studies evaluated
small numbers of patients with in-house proce-
dures. Because of its higher cost and its labour
intensity, PCR must exhibit superior accuracy in
order to justify its use in place of other means of
fungal marker detection. While combining anti-
gen detection and PCR may increase sensitivity,
the potential beneﬁt will be offset by the reduction
in speciﬁcity and the increase in cost. Future
evaluation would be facilitated by the develop-
ment of a commercial PCR kit.
The incidence of disease greatly inﬂuences the
positive predictive value and negative predictive
value of an assay [53,89,90]. When the incidence
of aspergillosis is 0.5%, as in kidney transplant
recipients [25], only one out of ten patients with
positive GM detection and one out of 70 with a
positive PCR result will actually suffer from
invasive aspergillosis. Antigen detection appears
to have a better positive predictive value at a low
incidence of disease compared with whole blood
PCR. Each assay has its drawbacks, with antigen
detection giving false-negative results and whole
blood PCR false-positive results; however, the
advantage of PCR is that a negative result nearly
always correlates with absence of disease.
PROPOSED CLINICAL USES AND
LIMITATIONS OF FUNGAL MARKER
DETECTION
BG and GM detection are useful tests for the
diagnosis of invasive aspergillosis in high-risk
patients with haematological malignancies. More-
over, a combination of both tests can be very
useful in identifying false-positive reactions
according to a single test. There has been no
study showing that the use of these methods has
any signiﬁcant impact on patient management or
survival. A systematic management approach to
high-risk patients, including BG and ⁄ or GM
detection, may improve patient outcome or
reduce the number of patients who receive
unnecessary treatment. Since invasive aspergil-
losis is a life-threatening disease, an aggressive
approach to identifying invasive mycoses as early
as possible and initiating antifungal therapy
promptly is required for patients at risk.
GM and BG detection should be undertaken
twice-weekly, as it appears that maximal beneﬁt
can be obtained when samples from patients are
tested regularly. One possible approach would be
to screen high-risk patients for the presence of
markers during the period of highest risk. The
selection of high-risk patients is essential, because
the incidence of disease becomes a very important
factor, especially when it is very low. Although
some questions remain to be answered (e.g.,
kinetics and release of the markers in vivo, the
performance of the assays in different patient
groups, the effect of antifungal treatment), the
broader use of these assays could contribute to a
better understanding of the pathogenesis of inva-
sive mycoses and an improvement in their diag-
nosis, treatment and prognosis. Once circulating
markers are detected and conﬁrmed, a diagnostic
workup should be performed, including a CT-
scan of the chest and bronchoscopy. If the pres-
ence of disease is conﬁrmed, antifungal treatment
should be started and monitoring of the circula-
ting marker continued.
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